These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 31917441

  • 1. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
    Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T.
    JAMA Ophthalmol; 2020 Mar 01; 138(3):244-250. PubMed ID: 31917441
    [Abstract] [Full Text] [Related]

  • 2. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T.
    Ophthalmology; 2019 Jun 01; 126(6):841-848. PubMed ID: 30677465
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
    Scoles D, Ying GS, Pan W, Hua P, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Martin DF, Maguire MG, Comparison of AMD Treatments Trials Research Group.
    JAMA Ophthalmol; 2020 Mar 01; 138(3):276-284. PubMed ID: 31999297
    [Abstract] [Full Text] [Related]

  • 4. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G.
    Cochrane Database Syst Rev; 2020 May 05; 5(5):CD012208. PubMed ID: 32374423
    [Abstract] [Full Text] [Related]

  • 5. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
    Ramakrishnan MS, Yu Y, VanderBeek BL.
    JAMA Ophthalmol; 2020 Mar 01; 138(3):237-242. PubMed ID: 32027349
    [Abstract] [Full Text] [Related]

  • 6. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL.
    JAMA Ophthalmol; 2019 Apr 01; 137(4):372-379. PubMed ID: 30676617
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM.
    JAMA Ophthalmol; 2021 Jan 01; 139(1):68-76. PubMed ID: 33211076
    [Abstract] [Full Text] [Related]

  • 8. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, all Archway Investigators.
    Ophthalmology; 2022 Mar 01; 129(3):295-307. PubMed ID: 34597713
    [Abstract] [Full Text] [Related]

  • 9. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
    Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J, TREND Study Group.
    Ophthalmology; 2018 Jan 01; 125(1):57-65. PubMed ID: 28893454
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group.
    JAMA Ophthalmol; 2020 Aug 01; 138(8):835-842. PubMed ID: 32644148
    [Abstract] [Full Text] [Related]

  • 11. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL.
    Ophthalmology; 2020 Feb 01; 127(2):198-210. PubMed ID: 31619357
    [Abstract] [Full Text] [Related]

  • 12. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S.
    JAMA Ophthalmol; 2020 Sep 01; 138(9):955-963. PubMed ID: 32729888
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
    Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU.
    JAMA Ophthalmol; 2020 Sep 01; 138(9):964-972. PubMed ID: 32729897
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, DENALI Study Group.
    Ophthalmology; 2012 May 01; 119(5):1001-10. PubMed ID: 22444829
    [Abstract] [Full Text] [Related]

  • 17. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2013 May 01; 120(5):1046-56. PubMed ID: 23352196
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD.
    Eldem BM, Muftuoglu G, Topbaş S, Çakir M, Kadayifcilar S, Özmert E, Bahçecioğlu H, Sahin F, Sevgi S, SALUTE study group.
    Acta Ophthalmol; 2015 Sep 01; 93(6):e458-64. PubMed ID: 25160859
    [Abstract] [Full Text] [Related]

  • 20. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL, Carius HJ, Skelly A, Ferreira A, Milnes F, Mitchell P.
    Adv Ther; 2017 Mar 01; 34(3):703-712. PubMed ID: 28144918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.